At a glance
ClinicalIndex Comparison RecordN/ACompleted· 718 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Retrospective Study To Describe Characteristics And Evaluate Real-World Outcomes in COPD Patients Initiating Trixeo Aerosphere (Budesonide/Glycopyrronium Bromide/Formoterol Fumarate) in Spain
In Brief
An observational study for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 718 participants across 15 sites.
Detailed Summary
The aim of the ORESTES study is to describe the characteristics of the COPD patients initiating Trixeo (BGF -budesonide/glycopyrronium/formoterol) in Spain and to assess their real-world outcomes up to 12 months afterwards. For that purpose,a descriptive, observational, multi-centre, longitudinal, retrospective cohort study involving \~20 Spanish centres and aiming to include between 500 and 700 patients, has been designed.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
20252026
First PostedMar 2024
Enrollment StartJul 2024
Primary CompletionDec 2024
TodayJul 2026
First PostedMar 20, 2024
Enrollment StartJul 2, 2024
Primary CompletionDec 16, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.3 years ago